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Vascular Effects of a Single Bout of Electronic Cigarette Use 
Ramon Eliseo Cossio., M.S. Kin. 
The University of Texas at Austin, 2018 
Supervisor: Hirofumi Tanaka 
As the use of electronic cigarettes (EC) begins to rise, the need to determine if they are 
indeed a safe alternative to traditional cigarettes (TC) is of utmost importance. As of 2016, 
over 15% of US adults age 18 or greater had tried electronic cigarettes. EC are commonly 
marketed as a safe alternative to TC, but recent studies have observed adverse effects on 
vascular functions from EC vapors similar to TC. Aim: To determine if EC vapor with 
5.4% and 0% nicotine by volume have adverse effects on key vascular functions in EC 
naïve subjects. Methods: 16 young apparently healthy subjects found to be free of 
cardiovascular and respiratory disease were recruited and screened to determine cigarette 
use. Each subject underwent three separate “vaping” trials with 5.4%, 0%, and sham EC. 
During each visit, endothelial function (via flow-mediated dilation) and arterial stiffness 
(via Cardio-Ankle Vascular Index) were measured at baseline, immediately post protocol, 
1 hour post protocol (1hr), and 2 hours post protocol (2hr). A repeated measures ANOVA
was used to determine if there were any significant time versus group interactions. Results: 
There were no significant changes in flow-mediated dilation (FMD), brachial blood 
vi 
pressure, and cardio ankle vascular index (CAVI) Score throughout the experiments lasting 
2 hours. Conclusion: Vaping electronic cigarettes regardless of nicotine content are not 
significantly different from each other and do not produce lasting effects over the course 
of a 2-hour trial. 
vii 
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Review of Literature 
Electronic Cigarette: Background 
Electronic cigarette (EC) use increased 900% among high school students in a 
period of four years. (HHS 2016) EC are marketed as safe alternative to tobacco cigarette 
TC but little research has been conducted on the chronic or acute effects on the 
cardiovascular system when exposed to EC vapor. To date, several chromatography studies 
have attempted to determine the overall aerosol content of various electronic cigarette 
products with varied levels of aldehydes, carbonyls, metals, and volatile organic 
compounds. (Goniewicz et al. 2013, Cheng 2014, Huang et al. 2018, Javed et al. 2017) 
Additionally, human and animal respiratory studies have found evidence of (EC) vapor as 
detrimental to lung function in the form of increased inflammation and irritation of the 
bronchial tubes. 
     There is a larger gap in the literature when determining the effects of EC vapor 
upon the human vasculature. It is well established that TC smoke causes excess 
inflammation within the endothelium of human arteries, which in turn causes endothelial 
dysfunction that leads to atherosclerosis. (Ambrose and Barua 2004) Thus, the research 
used to determine TC effects is uniquely suited to determine the effect of EC on 
cardiovascular function as the modes of delivery are similar. At the time of this writing, 
there had been only two human studies and one animal study that have studied the effect 
of EC on vascular function, inflammation, blood pressure, and pulse wave velocity. 
Carnevale et al. (2016) reported that the effects of EC and TC were not significantly 
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different in their effects on endothelial function as determined by flow-mediated dilation 
(FMD), but found a significantly reduced effect of EC on inflammatory biomarkers.  In 
terms of acute effects upon arterial stiffness, Vlachopoulos et al. (2016) found that EC was 
significantly less detrimental on pulse wave velocity (PWV) after five minutes when 
compared with TC. However, when the time of vaping was extended to thirty minutes, EC 
was found to be similar to the detrimental effects of TC. (Vlachopoulos et al. 2016) In a 
striking study conducted by Olfert et al. (2017), mice exposed to EC vapor for a total of 
four hours per day, five days a week, for a period of eight months observed a threefold 
increase in PWV of the mice exposed to EC vapor when compared with those exposed to 
air.  
While studies continue to show a close similarity to the effects of EC vapor to TC 
smoke, what is yet to be determined are the effects of EC vapor void of nicotine.  It is well 
accepted that many of the detrimental effects caused by TC are a result of toxic substances 
released when combustion of TC occurs. While EC do not burn, they still rely on the 
heating of constituents, which have been observed to produce potentially harmful 
substances. (Glasser et al. 2017) Goniewicz et al. (2014) studied 12 brands of electronic 
cigarettes and their produced aerosols and reported that all contained some amounts of 
aldehydes, volatile organic compounds, tobacco-specific nitrosamines, or metals. These 






     A strong indicator of emerging cardiovascular disease is vascular dysfunction in 
the form of reduced vasodilatory responses to physiological and/or pharmacological 
stimuli. (Endemann and Schiffrin 2004) In response to increased metabolic demands 
exerted upon the vasculature, the vasodilatory molecule nitric oxide (NO) is produced as a 
result of the increase in endothelial nitric oxide synthase activity. (Endemann and Schiffrin 
2004) NO is responsible for directly acting upon the vascular smooth muscle as a 
vasodilator, reducing platelet coagulation, and decreasing inflammation. (Endemann and 
Schiffrin 2004) In contrast, increases in vascular inflammation give rise to the reactive 
oxygen species (ROS) peroxynitrite, which increase low density lipid oxidation and further 
scavenges eNOS. C-reactive protein is also increased in a proinflammatory state resulting 
in the endothelial dysfunction.  
     Endothelial function can be used as an early prognostic tool for future 
cardiovascular disease and as such can be noninvasively measured utilizing flow FMD. 
(Ras et al. 2012, 2013) The hyperemia occurring after occlusion causes shear stress upon 
the arterial wall stimulating the release of endothelial nitric oxide synthase(eNOS) and 
further catalyzing NOS, which in turn vasodilates the vessels through relaxation of the 
smooth muscle cells. (Ras et al. 2012, 2013) FMD is performed by occluding forearm blood 
flow beginning at the antecubital fossa. An ultrasound probe is used to measure a cross 
section and record the brachial artery 6-10 cm above the occluded site. After a five-minute 
occlusion period the cuff is released, and measurement is commonly recorded for several 
minutes to determine peak blood flow and vascular dilation. (Ras et al. 2012, 2013) If 
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endothelial dysfunction is present, little to no change will be observed due to the decreased 
availability of eNOS.  
 TC and EC exposure has been shown to negatively and acutely affect endothelial 
function. (Carnevale et al. 2016, HHS 2011) Dysfunctional endothelial cells induced via 
TC have an increased expression of adhesion molecules leading to vascular inflammation, 
are unable to resist thrombosis, and result in reduced nitric oxide bioavailability. (HHS 
2011) TC smoke is known to have an abundance of free radicals such as superoxide, which 
reduce NO availability further increasing vascular oxidative stress. (Benowitz and Burbank 
2016) These effects are short lived in healthy non-smokers, but repeated exposure leads to 
arterial stiffening, which further reduces endothelial function as calcification of the 
endothelial wall prevents sheer stress from stimulating eNOS. (HHS 2011) 
 
Arterial Stiffness 
Arterial stiffness is the physical stiffening of vascular structure mediated by 
arteriosclerosis. (Tölle et al. 2015) Arteriosclerosis causes calcification and remodeling of 
the medial or endothelial lining of the arterial wall. Traditionally, arterial stiffness has been 
measured utilizing the reference standard measure of aortic PWV.  However, it is reliant 
on blood pressure at time of measurement, which may confound results attempting to 
determine the effects of pharmacological agents. (Shirai et al. 2011) Thus, the Cardio 
Ankle Vascular Index (CAVI) has been a novel development in the measurement of arterial 
stiffness as demonstrated by Kubozono et al. (2007) CAVI is measured from the aorta to 
the tibial artery located at the ankle and utilizes the diastolic and systolic blood pressures 
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measured at the brachial artery. (Shirai et al. 2011) CAVI can be summarized by the 
following equation; CAVI = a [(2ρ/ΔP) × ln(Ps/Pd) PWV^2] + b 
 Much like endothelial function, TC have been linked to arterial stiffness mediated 
by increased states of inflammation, platelet aggregation, and decreased eNOS expression. 
(Ambrose and Barua 2004) Stiffness of the vasculature in turn results in increased BP and 
stress upon the heart. Thus, smokers are at increased risk for cardiovascular diseases and 
early mortality. (HHS 2011) 
 
Nicotine 
The substance nicotine is and has been of profound interest in all research 
concerning tobacco products, as it is the main component linked to the addiction of said 
products. (Luttrell et al. 2014) Nicotine delivered via inhalation is transported to the lungs, 
where it is then absorbed into the blood stream, and continues on to the brain where it binds 
to nicotine acetyl cholinergic receptors (nAChRs) within 15-20 seconds (Benowitz and 
Burbank 2016, Benowitz 2010) nACHRs stimulate the release of dopamine resulting in 
reinforcement of a pleasurable experience. (Benowitz 2010, Dajas-Bailador and 
Wonnacott 2004) The half-life of nicotine in itself is two hours, owing to the repeated need 
to smoke. Typically, smokers spend 6-8 hours of the waking day delivering nicotine to the 
brain and stimulating nACHRs. Thus, nicotine addiction may result in repeated use of 
tobacco products, which in turn causes repeated exposures to harmful substances as 
repeated stimulation of nACHRs result in a blunting effect requiring larger doses of 
nicotine. (Benowitz and Burbank 2016) 
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Additionally, nicotine may be responsible for acute effects on the human 
cardiovascular system through sympathetic nervous system stimulation and release of 
catecholamines. The increase in norepinephrine and epinephrine stimulated by b1 receptor 
cause a rise in cardiac output by increasing heart rate and contractility. While stimulation 
of the a receptor results in peripheral vasoconstriction thereby increasing blood pressure 
by up to 5-10mmHg and cardiac filling (Benowitz and Burbank 2016, HHS 2010, Cryer et 
al. 1976) Paradoxically, coronary blood flow has been shown to increase in healthy subjects 
primarily due to the increase in cardiac output, which in turn stimulates flow-mediated 
vasodilation within the coronary artery. (Benowitz and Burbank 2016, Czernin and 
Waldherr 2003) As cigarette use increases over a lifetime, blunting of this phenomenon 
can be observed in smokers who have been diagnosed with cardiovascular disease. (Cryer 
et al. 1976, HHS 2010) 
Still nicotine itself has not been linked as the primary mediator of cardiovascular 
disease in smoking.  In fact, studies conducted on Swedish snuff (snus) did not see an 
association with myocardial infarction despite delivering the same level of nicotine 
concentrations as a TC. There is some evidence to suggest that a constant beta adrenergic 
and sympathetic stimulus may result in cardiac remolding and hypertension. (van Berlo et 
al. 2013, Jensen et al. 2012) However, determining nicotine’s role in cardiovascular disease 






Menthol’s role in TC is still relatively inconclusive with multiple studies observing 
an enhancement of inflammatory effect or no difference in effects when compared with a 
mainstream TC. (Lin et al. 2017, Gaworski et al. 1997, Pickworht et al. 2002, Abobo et al. 
2012) Of note, Fetterman et al. (2018) observed cell death, increased expression of 
Interluken-6, and impaired nitric oxide production when studying the effects of menthol 
independent TC. These findings were in agreement with an earlier study conducted by 
Leigh et al. (2016).  
Topical and oral studies on menthol have determined a slew of beneficial properties 
as an anti-inflammatory and vasodilatory agent. Johnson et al. (2009) found menthol to be 
a vasodilatory agent in human cutaneous vessels involving the possible stimulation of nitric 
oxide pathways and transient receptor potential melastatin 8 (TRPM8) when observed In 
Vivo. Xiong et al. (2017) found oral ingestion of menthol attenuated cold induced 
hypertension via the stimulation TRPM8, menthol was linked to reductions in reactive 
oxygen species and vasoconstriction.  
 
Propylene Glycol (PG) and Glycerol (VG) 
PG and VG are the main constituents of EC liquid and both have been found to be 
safe for human consumption via the FDA. However, these properties when heated have not 
been widely studied. PG mist and aerosol have been found to be irritants to human 
respiratory and ocular function when used as theatrical smoke and in firefighter training. 
(Varughese et al. 2005, Wieslander et al. 2001) The question as to whether PG and VG are 
 8 
safe for human use is not limited to aerosols as is evident in their historical use in foods 
and medicine. As vehicle for intravenous delivery, PG has been linked to sever side effects 
such as arrhythmias and seizures. (Arulanantham and Genel 1978, Martin and Finberg., 
1970)  
 More recently, researchers have found shisha pen vapor, whose liquid was 
composed of PG and VG, sufficient to cause airway irritation. (Kienhuis et al. 2015) While 
Goel et al. (2015) determined that there were significant reactive oxygen species created 
via heating of EC solvents PG and VG. Of concern are poor manufacturing techniques 
resulting in the production ethyl and propylene glycol mix being packaged into e-liquids. 
(Longo et al. 2016) Herrington and Meyers (2015) reported up to 70 unidentified 
compounds through chromatography studies in four of the most popular brands of EC. 
Those compounds included formaldehyde, acrolein, acetone, and propylene oxide. Finally, 
this year’s review by the National Academy of Sciences, Engineering, and Medicine has 
stated that decomposition of EC solvents leads to the formation of carbonyls such as 
formaldehyde and acrolein. (Daynard et al. 2018)  
 
Summary 
ECs and their aerosol constituents are now being heavily studied around the world. 
It has been confirmed by previous studies that EC with nicotine have effects on PWV, BP, 
and endothelial function. However, it is not clear whether these effects are direct results of 
nicotine or indirect effects of significant amount of potentially harmful substances being 
inhaled that can and will lead to development of CVD through chronic use. It is therefore 
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necessary to explore nicotine free ECs to greater extent in order to determine if they are 





















The use of electronic cigarettes has risen drastically over the last few years and is 
of particular concern because young adults are especially drawn to their use (HHS 2016, 
Regan et al. 2013). Traditional cigarettes are well studied and are known to cause 
significant harm to the cardiovascular system. Just one traditional cigarette can increase 
arterial stiffness within minutes of smoking and chronic use may lead to arteriosclerosis, 
which in turn may lead to the development of more sever cardiovascular diseases. 
(Kubozono et al. 2011) Currently, very little is known about the effect of electronic 
cigarettes in general and on cardiovascular function in particular. Electronic cigarettes are 
fruity favorable mild vapors that pose little irritation and therefore are more enjoyable of a 
habit (HHS 2016, Grana et al. 2014).  Accordingly, electrotonic cigarettes are perceived to 
be much less harmful.  However, recent letter to the editor has described adverse effects 
caused by electronic cigarettes in regard to arterial stiffness in chronic cigarette smokers 
(Vlachopouls et al. 2016).  Additionally, endothelial function decreased significantly when 
the subjects were exposed to electronic cigarettes (Carnevale et al. 2016).  More recently, 
Olfert et al. (2017) found significant increases in arterial stiffness in mice when they were 
chronically exposed to EC vapor for five days a week over eight months.  
A question that has not been explored is whether EC vapor void of nicotine have 
any adverse effects. Chromatography studies have found a variety of chemicals including 
carbonyls, aldehydes, and trace metals from the super-heating of PG and VG (Goniewicz 
et al. 2014, Glasser et al. 2017, Cheng 2014). In the case of TC smoke, the volatile 
compounds from combustion, such as tar and formaldehyde, are the main antagonist to 
vascular disease (Ambrose and Barua 2004). Currently, it is unknown if non-nicotine vapor 
has any impacts on vascular function. 
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Therefore, the primary purpose of the present study was to assess the acute changes 
in arterial stiffness and endothelial function after smoking EC for a vaping period of six 
minutes. To maximize the effects of EC and to minimize the downregulation associated 
with chronic exposure, we studied subjects who are naïve to EC and TC.  Utilizing three 
conditions; an EC with 5.4% nicotine by volume, an EC with 0% nicotine by volume, and 
Sham menthol inhaler without vapor or nicotine. We hypothesized that both vaping 
conditions would cause significant changes to arterial stiffness and endothelial function 





Subjects and Procedures 
A total of 16 young apparently healthy adults were recruited via convenience 
sample at the University of Texas and the surrounding Austin, Texas area. All subjects 
were between the ages of 20-30 years and were asked to complete a health history 
questionnaire to determine their eligibility. Volunteers with overt cardiovascular and 
pulmonary diseases (hypertension, diabetes, asthma) and those who had regularly used 
tobacco and nicotine products within the last 6 months and who were taking cardiovascular 
acting drugs were excluded. Additionally, female participants were tested only during the 
follicular phase of their menstrual cycles to minimize the confounding hormonal effects.  
Subjects reported to the laboratory having fasted for a minimum of 8 hours and 
having abstained from vigorous activity, caffeine, alcohol for a minimum of 12 hours. 
Upon the subjects’ arrival at the Cardiovascular Aging Research Laboratory, their height 
and body weight were recorded followed by a supine resting period of ten minutes in a 
dimly lit temperature-controlled room. At the completion of the rest periods, a baseline 
measurement of arterial stiffness and endothelial function were taken. Upon completion of 
baseline assessments, subjects were escorted to a previously selected outdoor area and 
asked to vape an electronic cigarette, which was a combination of a battery (Cirrus 3) and 
cartridge (Menthol Flavor Clear Draw Max 5.4% or 0%) or a sham cigarette (Harmless 
Cigarette Quit Smoking Aid). EC containing 5.4% nicotine by volume (NBV) was selected 
as it is considered a higher strength vapor, that would likely produce a robust response. 
Doses of 16 mg and .8mg or about 1.6% and <1% NBV respectively have been used in 
previous studies. (Olfert et al. 2016, Crippa et al. 2018). The vaping protocol was a total of 
six minutes in length, consisting of four second inhalations every twenty seconds 
culminating into eighteen puffs in total. The researcher verbally instructed all subjects 
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when to inhale and exhale, with an emphasis on drawing vapor into the lungs. The order 
of ECs was randomized.    
Subjects were then asked to return to the laboratory for an acute post EC 
assessment. Assessments were repeated post one hour and post two hours to determine 
time (i.e., residual) effect on the vasculature. Subjects completed this protocol a total of 
three times nonconsecutively, with a minimum of forty-eight hours between testing days. 
All measures were recorded by a single researcher. 
  
Cardioankle Vascular Index (CAVI)  
All measurements were taken with a computerized semi-automatic noninvasive 
body pressure monitoring device VaSera (Fakuda Denshi, Bunkyo-ku, Tokyo, Japan). 
CAVI is a measure of arterial stiffness and was calculated from pulse wave distance 
divided by transit time. Blood pressure cuffs placed upon ankles and arms were inflated to 
a pressure of 30-50 mmHg in order to record pulse waves but not affect hemodynamics 
(Shirai et al. 2006). Pulse wave velocity was measured by summing closure of the aortic 
valve and brachial notch appearance upon the wave form, plus the time between the rise of 
the brachial and ankle pulse wave. The CAVI score above a 9 indicates possible 
arteriosclerosis, and CAVI scores below 8 signify no measurable arterial stiffening. (Shirai 
et al. 2011, Saiki et al. 2016).  
 
Flow-Mediated Dilation  
Flow-mediated dilation (FMD) is a noninvasive method to assess vascular 
endothelium dependent vasodilation by measuring the brachial artery’s responsiveness to 
ischemic stress.  By use of an automated diagnostic ultrasound system (UNEXEF-38G, 
UNEX corporation, Sakae Naka-ku, Nagoya, Japan). The system is equipped with an 
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electric linear array transducer operating at 10 MHz. While subjects rest in supine position, 
a blood pressure cuff was placed on the forearm with the proximal edge of the cuff above 
the subject's antecubital fossa and second blood pressure cuff was placed on the 
contralateral arm for standard blood pressure measurements (Tomiyama et al. 2015). 
Cross-sectional images of the artery were acquired utilizing the automated probe, which 
self-adjusted to provide a clear longitudinal image of the artery and begin baseline 
measurements (Tomiyama et al. 2017). After the acquisition of baseline measurement, the 
cuff inflated to 50 mmHg above resting systolic blood pressure for 5 minutes. Upon cuff 
deflation, ultrasound-derived measurements of the brachial artery diameters and blood 
flow velocity were taken for 2 minutes. FMD was calculated by the following equation: 
(maximum diameter – baseline diameter) / baseline diameter x 100 (Tomiyama et al. 2015). 
 
Statistical Analyses 
Results were analyzed IBM SPSS statistics version 24, utilizing a repeated 
measures ANOVA for all variables comparing time and group effects. All p-values 
reported utilizing Greenhouse-Geisser correction with any significant effects further 




 Selected subject characteristics are presented in Table 1.  Subjects were young 
healthy and had normal body weight.  (Table 3). CAVI scores tended to increase during 
the post measurement period but there was not a significant group x time interaction 
(p=.31) (Figure 1 and Table 2). FMD tended to decrease slightly post vaping in all 
conditions but results were not found to be statistically significant (Figure 2 and Table 2). 
Both systolic and diastolic BP tended to increase post vaping but was not significant 





In the present study, our working hypothesis was not supported by the results as no 
significant changes in subclinical vascular functions were observed with the ECs 
containing 5.4% and 0% nicotine. Even though we observe slight changes in all variables, 
including CAVI, systolic and diastolic BP increasing immediately post a vape and FMD 
declining, these changes were modest at best and did not reach statistical significance. 
Interestingly, the sham condition displayed the same pattern of increase post vape as other 
ECs containing nicotine. We believe that this may be attributed to our novel method of 
sham control involving a menthol inhaler and the use of blinded EC naïve subject. In other 
studies, the sham control was the use of an expended or empty EC device, which can be 
recognized easily by th participants (Carnevale et al. 2016, Vlachopoulos et al. 2016, 
Crippa. 2018).  
 CAVI measurements used in the present study are well established in detecting 
arterial stiffening and are relatively non-technical in nature. Unlike carotid-femoral pulse 
wave velocity (PWV), the placement of femoral and carotid tonometers is not necessary, 
and measurements are less tedious, accounting for less researcher bias. TC studies utilizing 
both brachial-ankle PWV and CAVI have shown strong correlations between the methods, 
and both measures increased significantly after tobacco smoking (Kubozono et al. 2011). 
Given this, we could compare our use of CAVI to Vlachopouls et al. (2016) who used 
PWV.  Although they observed a significant increase in PWV after five minutes of vaping, 
it is a letter to the editor and has very limited information to interpret the data. More 
recently, Franzen and colleagues (2018) observed elevated PWV but did not report 
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significant changes. We believe that our lack of significance may be found in the chosen 
statistical analysis determining the group x time interaction rather than significant changes 
from baseline measurement to post measurement.   
 We did not observe significant difference between conditions when it came to FMD 
change likely caused by an inappropriate does of nicotine. While we did not use a TC for 
comparison as others studies have, we did observe no significant differences in FMD 
between the 5.4% and 0% conditions. This begs to question if a 0% EC would display 
similar changes in comparison to a TC without nicotine. Of noted strength to our form of 
measurement is the use of the new UNEX Semi-Automated FMD device, as it is the device 
that selects the appropriate image for measurement, has an automated occlusion control, 
and records post occlusion automatically. Unlike the common form of measure 
(>200mmHg), the one used by our occlusion pressure was 50 mmHg above the baseline 
SBP measure, likely attributing to lower % change (Harris et al. 2010). Like CAVI, all 
measures were taken by one researcher and analysis was automatically generated real time, 
allowing little room for introducing investigator bias or variability.  
Visible increases in SBP and DBP were observed in the 5.4% EC condition but 
only DBP was found to have a time x group significance, further analysis and review of 
pairwise comparisons resulted in no significant results. This is in contrast to a recent study 
by Crippa et al. (2018) who found significant changes in both SBP (9.6±4 mmHg) and 
DBP (7.1±3.9 mmHg) when comparing with placebo trials in subjects with mild 
hypertension. Lack of hemodynamic responses to the high strength nicotine product used 
in the present study may suggest inadequate dosing for subjects who were naïve to EC or 
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tobacco smoking. However, a few subjects experienced sever irritation during the bout of 
5.4% NBV vapor. This may be a cause for concern as EC users tend to vape more regularly 
and draw in longer puffs, with experienced users inhaling for as long as eight seconds, 
double the time of our current protocol (Olfert et al. 2018). 
 Another strength of this study is the use of young 20-30 year old subjects, who were 
healthy, active, and the majority naïve to both EC and tobacco smoking. We believe this 
may be a unique sample demonstrating the controversial cardioprotective qualities of 
frequent exercise. A study by Park et al. (2014) observed no significant differences in PWV 
between active smokers and active non-smokers leading the researchers to conclude that 
regular exercise may be protective against the negative effects of TC. Many of the 
previously mentioned studies utilized current or former smokers (Crippa et al. 2018, 
Franzen et al. 2018, Vlachopouls et al. 2016). It seems necessary to classify subjects in 
terms of regular physical activity in future studies to rule out if any detrimental effects exist 
for the active population of EC users. The use of a familiarization trial was implemented 
to ensure proper inhalation of the EC product. As mentioned, the use of smokers and 
smaller levels of NBV in previous studies likely resulted in better inhalation of vapor 
product, which we were not able to replicate. 
 Limitations of this study were evident in use of non-consecutive trials which lasted 
just under 3 hours. As required by the protocol and minimum of 48 hours was given 
between trials, often leading to scheduling conflicts. Thus, a number of subjects finished 
their trials over an extended period of time.  Another important limitation is a small sample 
size.  Lastly, we were limited in our vaping location, and the protocol required subjects to 
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walk close to 50 m to and from the vaping location. Future studies should make every effort 
to reduce movement of subject and if possible test and measure subject in the same location.  
 The safety of electronic cigarettes remains in question, especially with a multitude 
of vapor liquid and device options available in the market. This study has determined that 
electronic cigarettes regardless of nicotine presence are not significantly different from one 
another as evident by the similar trend in responses regardless of condition. Future studies 
would benefit in comparing non-nicotine vapors at various heating temperatures as a study 




Tables and Figures 
Table 1. Selected Subject Characteristics 
 
Variable   n or Mean ± S.D. 
Participants (n)  16 
Sex (n)  M (9) F (7) 
Age (yr)  24±2.5 
Height (m)  1.73 ± 0.08 
Body weight (kg)  69.5 ± 10.3 
BMI (kg/m2)   23.2 ± 2.8 
SBP  117 ± 8 
DBP  68 ± 4 
Heart Rate(bpm)  54 ± 8 
    
BMI= Body Mass index, SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, 




Table 2. Changes in vascular and hemodynamic measures during the experimental periods 
 








5.4% 5.82 0.69 6.23 0.76 6.04 0.88 5.90 0.75 
0% 5.91 0.59 6.04 0.74 6.03 0.53 6.11 0.66 
Sham 5.70 0.64 5.93 0.89 5.95 0.81 5.98 0.78 
FMD 
5.4% 5.63 1.75 5.23 1.68 6.12 2.14 5.56 2.57 
0% 5.73 2.82 4.91 2.03 4.98 2.21 5.24 2.49 
Sham 6.64 2.45 5.60 2.40 6.64 2.01 6.16 3.24 
SBP 
5.4% 119 9.64 124 9.46 121 9.56 121 9.03 
0% 115 7.65 118 9.64 120 7.84 119 9.58 
Sham 117 6.24 119 7.46 120 7.25 120 7.07 
DBP 
5.4% 69 4.34 73 4.97 71 6.15 70 5.40 
0% 66 4.09 68 4.71 70 5.09 68 4.67 
Sham 68 3.42 68 5.64 71 6.05 69 5.13 
          
CAVI = cardio ankle vascular index, FMD = Flow-mediated dilation, SBP = systolic 
blood pressure, DBP = diastolic blood pressure, 5.4% = Nicotine by volume,                   













Figure 1. Mean±S.D. Cardio Ankle Vascular Index (CAVI) scores at baseline, 


















Figure 2. Mean±S.D. flow-mediated dilation at baseline, immediately post, at 1 hr, and at 















Figure 3. Mean±S.D. brachial systolic blood pressure at baseline, immediately post, at 1 


















Figure 4. Mean±S.D. brachial diastolic blood pressure at baseline, immediately post, at 1 
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